TEL AVIV, Feb 3 (Reuters) - Teva Pharmaceutical Industries (TEVA.O) has been notified in a warning letter of weaknesses at its Jerusalem oral solid dosage plant (OSD) after an inspection last year by the U.S. Food and Drug Administration.